![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, October 25, 2019 12:46:16 PM
I am looking forward to seeing the what develops and my bet is the longs are going to be very happy.
Leo said that he will provide more clarity in the coming weeks.
“A new direction, a new understanding of what’s going on, actually growing the company, not shrinking it.”
Leo's riddle is still mainly unanswered. I did not see any hints in the 10 K, but the Locust Walk PR did have a few statement which points to a more aggressive plan to develop partnerships. I expect more news in the upcoming months.
"...we continue to diligently work toward completing other transactions that would unlock additional shareholder value. As such, we are thrilled to engage Locust Walk—with their proven track record and global footprint.”
“We are very selective in deciding which companies to work with,” said Chris Ehrlich, Managing Director and Global Head of Biopharma at Locust Walk. “We look forward to working with Innovation Pharmaceuticals to help them determine the market potential and the best path forward to create value.”
http://www.ipharminc.com/press-release/2019/9...ction-firm
From the Locust Walk web site, an example of a complex partnership:
" October 7, 2010: SGI and JCVI announce formation of new company, SGVI, to develop next generation vaccines
SGVI announces three-year collaboration with Novartis on the development of influenza vaccines using synthetic genomics technology. The agreement, supported by an award from the U.S. Biomedical Advanced Research and Development Authority (BARDA), could ultimately lead to a more effective response to seasonal and pandemic flu outbreaks.
https://www.locustwalk.com/our-engagements/sy...-novartis/
My guess is IPIX has several suitors, domestic and international, who are proposing a variety of offers leading IPIX to hire a third party to structure the best deal and facilitate the closing of a deal. A deal which almost certainly will include Brilacidin for Inflammatory Bowel disease.
From the 9/10/2019 PR
Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticalsstated,"If oral Brilacidin performs in UC like we believe it can, we should find ourselves in a strong negotiating position toward securing additional licensing agreements in a market that runs into the tens of billions of dollars.”
http://www.ipharminc.com/press-release/2019/9...arter-2019
All IMO,Farrell
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM